ICOS monotherapy and ICOS/PD-1 combination therapy exhibited a similar effect on CD8+ T-cell kinetics in tumors; however, an early significant increase of the CD8+ minibody uptake in the tumor-draining lymph node was observed following ICOS/PD-1 combination therapy with a less distinct increase following ICOS monotherapy. This evidence concerns the gene CD8A and neoplasm.